Literature DB >> 28215033

Anti-mutated citrullinated vimentin antibodies in antiphospholipid syndrome: diagnostic value and relationship with clinical features.

Cristiano Alessandri1, Nancy Agmon-Levin2, Fabrizio Conti1, Carlo Perricone3, Elena Ortona4, Monica Pendolino1, Antonella Capozzi5, Federica Delunardo4, Riccardo Mancini1, Simona Truglia1, Francesca Romana Spinelli1, Fulvia Ceccarelli1, Maurizio Sorice5, Yehuda Shoenfeld2, Guido Valesini1.   

Abstract

Antiphospholipid antibodies (aPLs) are a heterogeneous group of autoantibodies essential for the diagnosis of antiphospholipid syndrome (APS) but do not predict clinical manifestations or disease progression. Hence, the co-presence of other antibodies may prove useful. Autoimmunity directed toward vimentin and other citrullinated peptides was established in rheumatoid arthritis (RA) and in other autoimmune conditions including systemic lupus erythematosus (SLE). We have previously described the presence of autoantibodies directed against vimentin/cardiolipin complex in patients with antiphospholipid syndrome (APS), but there are no data on the role of citrullinated vimentin in APS. Thus, we evaluated the prevalence and clinical significance of anti-MCV in APS patients. The study group consisted of 79 unselected outpatients with APS. Control groups included 25 patients with SLE, 30 patients with RA, and 20 healthy subjects age- and sex-matched. To detect anti-MCV, anti-vimentin, anti-vimentin/cardiolipin, and anti-CCP2 antibodies, commercial or homemade enzyme-linked immunosorbent assays (ELISA) were performed. Anti-MCV antibodies were found in a high percentage of APS patients (26.6%). A significant correlation between anti-MCV and anti-vimentin/cardiolipin serum levels was observed (p = 0.029). Moreover, vimentin reactivity was increased by its citrullination or conjugation with cardiolipin (p = 0.01 and p < 0.001, respectively). Interestingly, anti-MCV was found associated with the presence of arthritis (p = 0.011) and anti-vimentin/cardiolipin was highly specific for the presence of arterial or venous thrombosis in APS (p = 0.003 and p = 0.002, respectively). The detection of additional autoantibodies may contribute to clinical assessment of APS patients. Citrullination may occur in APS and play a role in the pathogenesis of this condition. KEY POINTS: •Anti-MCV antibodies can be found in APS patients and are associated with the presence of arthritis. •Anti-vimentin/cardiolipin is strongly associated with the presence of thrombosis (both arterial and venous). •Citrullination occurs in APS, participate in disease pathogenesis, and influence clinical picture.

Entities:  

Keywords:  APS; Anti-CCP; Anti-MCV; aPL

Mesh:

Substances:

Year:  2017        PMID: 28215033     DOI: 10.1007/s12026-017-8899-x

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  29 in total

1.  Cardiolipin and its metabolites move from mitochondria to other cellular membranes during death receptor-mediated apoptosis.

Authors:  M Sorice; A Circella; I M Cristea; T Garofalo; L Di Renzo; C Alessandri; G Valesini; M Degli Esposti
Journal:  Cell Death Differ       Date:  2004-10       Impact factor: 15.828

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 3.  Citrullinated Autoantigens: From Diagnostic Markers to Pathogenetic Mechanisms.

Authors:  Sylviane Muller; Marko Radic
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

4.  Anti-CCP antibodies as a marker of rhupus.

Authors:  J Amaya-Amaya; N Molano-González; J-S Franco; M Rodríguez-Jiménez; A Rojas-Villarraga; J-M Anaya
Journal:  Lupus       Date:  2015-02-09       Impact factor: 2.911

5.  Ca2+-dependent deimination-induced disassembly of intermediate filaments involves specific modification of the amino-terminal head domain.

Authors:  M Inagaki; H Takahara; Y Nishi; K Sugawara; C Sato
Journal:  J Biol Chem       Date:  1989-10-25       Impact factor: 5.157

6.  Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.

Authors:  Elena Bartoloni; Alessia Alunno; Onelia Bistoni; Nicola Bizzaro; Paola Migliorini; Gabriella Morozzi; Andrea Doria; Alessandro Mathieu; Milvia Lotzniker; Flavio Allegri; Valeria Riccieri; Claudia Alpini; Armando Gabrielli; Marilina Tampoia; Roberto Gerli
Journal:  Autoimmun Rev       Date:  2012-02-27       Impact factor: 9.754

Review 7.  Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis.

Authors:  Erik R Vossenaar; Walther J van Venrooij
Journal:  Arthritis Res Ther       Date:  2004-04-19       Impact factor: 5.156

8.  Citrullination of synovial proteins in murine models of rheumatoid arthritis.

Authors:  Erik R Vossenaar; Suzanne Nijenhuis; Monique M A Helsen; Annemarie van der Heijden; Tatsuo Senshu; Wim B van den Berg; Walther J van Venrooij; Leo A B Joosten
Journal:  Arthritis Rheum       Date:  2003-09

9.  Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis.

Authors:  Cristiano Alessandri; Maurizio Sorice; Michele Bombardieri; Paola Conigliaro; Agostina Longo; Tina Garofalo; Valeria Manganelli; Fabrizio Conti; Mauro Degli Esposti; Guido Valesini
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

10.  Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome.

Authors:  Vera M Ripoll; Anastasia Lambrianides; Silvia S Pierangeli; Katie Poulton; Yiannis Ioannou; Wendy E Heywood; Kevin Mills; David S Latchman; David A Isenberg; Anisur Rahman; Ian P Giles
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

View more
  8 in total

1.  Frequency of serological markers of rheumatoid arthritis in patients with IgA anti-β2 glycoprotein I antibodies.

Authors:  Sarra Melayah; Mariem Ghozzi; Amani Mankaï; Fatma Mechi; Ibtissem Ghedira
Journal:  J Clin Lab Anal       Date:  2022-06-06       Impact factor: 3.124

2.  Editorial: Cutting edge in systemic lupus erythematosus.

Authors:  David P D'Cruz; Annegret Kuhn
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 3.  Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS".

Authors:  Roberta Misasi; Agostina Longo; Serena Recalchi; Daniela Caissutti; Gloria Riitano; Valeria Manganelli; Tina Garofalo; Maurizio Sorice; Antonella Capozzi
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

4.  Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome-Multicenter, Real-Life Long-Term Follow-Up.

Authors:  Stanley Niznik; Micha J Rapoport; Orly Avnery; Aharon Lubetsky; Soad Haj Yahia; Martin H Ellis; Nancy Agmon-Levin
Journal:  Front Immunol       Date:  2022-04-19       Impact factor: 8.786

5.  Detection of Anti-Vimentin Antibodies in Patients with Sarcoidosis.

Authors:  Anna Starshinova; Anna Malkova; Ulia Zinchenko; Sergey Lapin; Alexandra Mazing; Dmitry Kudlay; Piotr Yablonskiy; Yehuda Shoenfeld
Journal:  Diagnostics (Basel)       Date:  2022-08-11

Review 6.  Citrullination and PAD Enzyme Biology in Type 1 Diabetes - Regulators of Inflammation, Autoimmunity, and Pathology.

Authors:  Mei-Ling Yang; Fernanda M C Sodré; Mark J Mamula; Lut Overbergh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 7.561

7.  IgA is the predominant isotype of anti-β2 glycoprotein I antibodies in rheumatoid arthritis.

Authors:  Sarra Melayah; Maha Changuel; Amani Mankaï; Ibtissem Ghedira
Journal:  J Clin Lab Anal       Date:  2020-01-22       Impact factor: 2.352

8.  Anti-vimentin/cardiolipin IgA in the anti-phospholipid syndrome: A new tool for 'seronegative' diagnosis.

Authors:  Antonella Capozzi; Gloria Riitano; Silvia Mancuso; Serena Recalchi; Valeria Manganelli; Tina Garofalo; Cristiano Alessandri; Agostina Longo; Roberta Misasi; Fabrizio Conti; Simona Truglia; Maurizio Sorice
Journal:  Clin Exp Immunol       Date:  2021-06-29       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.